LLY's Weight-Loss Drugs: 66% of Revenue and Growing
💡 Puntos Clave
Eli Lilly's weight-loss and diabetes franchise now accounts for nearly two-thirds of revenue, with accelerating growth and a new pill expanding the market, but concentration risk remains.
What Happened: Weight-Loss Drugs Dominate Lilly's Q1
Eli Lilly reported first-quarter 2026 results showing Mounjaro and Zepbound generated a combined $12.8 billion in revenue, representing nearly two-thirds of the company's $19.8 billion total revenue. Mounjaro, for type 2 diabetes, saw revenue jump 125% year over year to $8.7 billion, while Zepbound, for weight loss, grew 80% to $4.2 billion.
The franchise's momentum is accelerating. Combined revenue more than doubled from $6.2 billion in Q1 2025 to $12.8 billion in Q1 2026. For full-year 2025, the pair brought in $36.5 billion, over half of Lilly's $65.2 billion revenue.
Total Q1 revenue rose 56% year over year, driven by a 65% increase in volume, partially offset by a 13% decline in realized prices. Earnings per share soared 170% to $8.26, and adjusted EPS rose 156% to $8.55.
Management raised full-year 2026 revenue guidance to $82-$85 billion, up $2 billion from prior forecast, and lifted adjusted EPS guidance by $2. The new revenue range implies about 28% growth at the midpoint.
In April, the FDA approved Foundayo, Lilly's once-daily GLP-1 pill for weight loss, with self-pay pricing starting at $149 per month. The pill can be taken anytime without food or water restrictions, potentially expanding the market beyond injection users.
Why It Matters: Concentration Risk vs. Growth Opportunity
The weight-loss franchise is now the overwhelming driver of Lilly's business, accounting for nearly two-thirds of revenue. This concentration means the stock's performance is tightly tied to the success of tirzepatide (Mounjaro/Zepbound) and now Foundayo. Any competitive threat, regulatory setback, or pricing pressure could significantly impact the stock.
On the positive side, the growth is extraordinary. Mounjaro's revenue acceleration from 99% in FY2025 to 125% in Q1 2026 shows no signs of slowing. The new pill Foundayo opens a larger addressable market, especially among patients who prefer oral over injectable medications.
Pricing pressure is a key risk. Realized prices fell 13% in Q1, including cash-pay reductions for Zepbound. So far, volume growth has more than compensated, but if volume growth decelerates, the impact on revenue and margins could be severe.
At $1,184 per share, Lilly trades at about 33 times the midpoint of adjusted EPS guidance. That's a premium multiple, but it's attached to a company guiding for 28% revenue growth. Investors are paying up for a high-growth story, but they must accept the concentration risk.
Fuente: The Motley Fool
Análisis generado por el modelo cuantitativo de Bobby AI, revisado y editado por nuestro equipo de investigación. Esto no constituye asesoramiento financiero. Investigue por su cuenta antes de tomar decisiones de inversión.
Bobby Insight
Lilly's weight-loss franchise is a powerful growth engine, but investors must monitor pricing and competition closely.
The 28% revenue growth guidance and new pill Foundayo provide a strong runway. However, the 13% price decline and concentration risk warrant caution. The premium valuation is justified as long as growth continues, but any slowdown could trigger a re-rating.
¿Cómo Me Afecta?
